BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans

RICHMOND, Calif.--(BUSINESS WIRE)-- BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that the company will host an online key opinion leader (KOL) event for analysts, investors, and other interested parties on its first-in-class apelin receptor agonist BGE-105. The event will be broadcast online on Wednesday, January 4, 2023 at 2:00 PM ET.

At the virtual event, BioAge leadership will present on Phase 1b trial design and recently announced topline data showing that BGE-105 significantly improved multiple measures of muscle atrophy in older volunteers on 10 days of bed rest, and give insight into the design and objectives of a Phase 2 clinical study for prevention of ICU diaphragmatic atrophy and critical illness myopathy.

In addition, KOLs William J. Evans, PhD and Ewan Goligher, MD, PhD, FRCPC will provide an overview of the clinical impact and current treatment landscape for conditions related to muscle aging, including the significant unmet medical need for therapies for intensive care unit (ICU) diaphragmatic atrophy and critical care myopathy. Patients undergoing mechanical ventilation in the ICU undergo rapid disuse atrophy of the diaphragm and peripheral muscles, which is predictive of adverse outcomes including extended time on ventilator, extended time in the ICU, long recovery time, and substantially increased mortality. No therapies are available for either condition.

William Evans, PhD is Adjunct Professor of Human Nutrition at UC Berkeley and Medicine (Geriatrics) at Duke University. Dr. Evans was the first to describe sarcopenia, the age-related loss of muscle mass and strength that drives functional decline and loss of independence in older adults. His research has examined the effects of bed rest on body composition, muscle metabolism and functional capacity in older people, biomarkers for changes in muscle mass and function, and the etiology of late life dysfunction, and has revealed connections between sarcopenia and other diseases of aging. Previously, he was President of the Muscle and Health Division at KineMed and VP and Head of GlaxoSmithKline’s Muscle Metabolism Discovery Performance Unit. In 2005, he testified before the Senate Select Committee on Aging about strategies to save Medicare through prevention of chronic diseases associated with aging.

Ewan Goligher, MD, PhD, FRCPC is an internationally recognized expert in critical care medicine and a leader in the field of lung and diaphragm injury during mechanical ventilation (MV). His research at the University of Toronto and University Health Network has contributed significantly to the field of diaphragm dysfunction, including the development of novel ultrasound techniques for assessing diaphragm muscle structure and function in patients on MV. He has extensive experience leading clinical trials, including a study that characterized diaphragmatic changes in mechanically ventilated patients, resulting in the seminal description of the prevalence of diaphragm atrophy and injury during MV. He was the first to describe the relationship between changes in diaphragm thickness and the risk of complications of respiratory failure, including prolonged ventilation, reintubation, and tracheostomy, and first to propose the concepts of diaphragm myotrauma and diaphragm-protective ventilation.

BGE-105 is a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. Phase 1b trial data released to date demonstrate that in healthy volunteers 65 and older on 10-day strict bed rest, BGE-105 prevented muscle atrophy as reflected by improvements in multiple parameters, including the dimensions of leg muscles, muscle quality, and muscle protein synthesis. BGE-105 was well-tolerated in the study, consistent with prior Phase 1 trials showing that it was safe and well-tolerated in 198 subjects.

A moderated audience Q&A session will follow the live presentations. Interested parties can register for the event here.

About BioAge Labs, Inc.

BioAge is a clinical-stage biotechnology company developing a pipeline of therapies to extend healthy lifespan by targeting the molecular causes of aging. BioAge uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records, to map the key molecular pathways that impact healthy human aging. By targeting the mechanisms of aging with a large, mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or prevent age-related disease in entirely new ways. BioAge has multiple programs targeting muscle, immune, and brain aging, including the clinical-stage apelin receptor agonist BGE-105 and a differentiated CNS-penetrant NLRP3 inhibitor. Investors include Andreessen Horowitz, Kaiser Foundation Hospitals, Caffeinated Capital, Khosla Ventures, and others.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005424/en/